According to the Zhixin Finance APP, JXR's (01951) stock has risen nearly 6%, as of press time, up 5.96% to HKD 3.38 with a turnover of HKD 54.93 million.

In recent news, the Shanghai Medical Insurance Bureau, in collaboration with the Human Resources and Social Security and Health departments, issued a notification on including 12 assisted reproduction medical services in the scope of medical insurance and work injury insurance payment, as part of implementing supportive measures for active fertility. This will take effect from June 1, 2024. According to incomplete statistics, Beijing, Guangxi, Inner Mongolia, Gansu, Jiangxi, and Shanghai have already included assisted reproduction in their medical insurance reimbursement.

According to CSC Securities Research, looking ahead to 2024, the policy of encouraging childbirth and including assisted reproduction in medical insurance will continue to catalyze growth in the industry, and business prospects are expected to further improve. The company will use Chengdu as a model to develop a fertility integration business centered on assisted reproduction, promote it in hospitals in other regions, and accelerate the development of new businesses through its advantages in the assisted reproduction medical services market, creating new revenue growth points. In the medium to long term, the company will expand its business network through self-building or acquisition, improve its talent recruitment and training system, and provide integrated medical services.